Expression of “Connexin 43” in Colorectal Carcinomas: Histopathological and Immunohistochemical Study

Essam Ayad, Ahmed Naeem Eesa, Rabab Radi*, Lubna Omar El Farouk Abdel-Salam

Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt

Abstract

BACKGROUND: Colorectal cancer is one of the most common cancers worldwide and leading cause of cancer related deaths. Connexins are integral membrane proteins that form channels between adjacent cells. Gap junction intercellular communication plays essential roles in tissue homoeostasis and regulation of cell growth and differentiation. Connexins can act as either tumor suppressors or tumor promoters. The human connexin protein family contains 21 members, of which the most widely studied is connexin 43 (Cx 43).

OBJECTIVES: Investigation of immunohistochemical expression of Cx 43 in cases of colorectal adenoma and carcinoma and correlation of this expression with the clinico-pathological aspects of the tumors.

MATERIALS AND METHODS: Seventy formalin fixed paraffin embedded BC tissue sections were randomly collected. All the available data were collected from the patients’ reports. The paraffin blocks were sectioned and stained with hematoxylin and eosin stains for histologic evaluation. Additional sections were immunostained with Cx 43.

RESULTS: Cx 43 expression was negative in all studied cases.

CONCLUSION: Cx 43 is a tumor suppressor that is lost early in colorectal carcinogenesis and can be considered as potential target for cancer chemoprevention and chemotherapy aiming at restoration of normal connexin expression and functional gap junctions.

Introduction

Colorectal cancer (CRC) is one of the most common cancers worldwide. More than 1 million new cases were reported annually resulting in about 600,000 deaths worldwide per year [1]. Worldwide, CRC is the second most common cancer in women and the third most common in men [2].

In Egypt, colorectal carcinoma accounts for 6.48% of all cancers according to the National Cancer Institute Cairo University [3].

Loewenstein and Kanno were the first to propose the idea that gap junction intercellular communication (GJIC) regulates tumor growth more than 50 years ago in a study, in which they demonstrated the loss of electrical coupling occurring in rat liver tumors [4]. Connexins are integral membrane proteins that form channels between adjacent cells. GJIC plays essential roles in tissue homoeostasis and regulation of cell growth and differentiation [5]. In addition, connexins form functional channels at the non-junctional areas of the plasma membrane, these so-called hemichannels provide a communication pathway between the intracellular and extracellular milieus that is an important in autocrine and paracrine signaling [6].

Connexins can act as either tumor suppressors or tumor promoters depending on the isoform, cancer stage, and tissue. In addition to the emerging prognostic value of connexins in cancer, several studies indicate that connexin targeting might have considerable therapeutic implications [7], [8]. Cancer cells often display a loss of GJIC due to the dysregulation of connexin expression at multiple levels [9].

The human connexin protein family contains 21 members, of which the most widely studied is connexin 43 (Cx 43) [5].

Several studies reported that Cx 43 acts as tumor suppressor that is downregulated in colorectal carcinoma they are considered as potential targets for cancer chemoprevention and chemotherapy [10], [11], [12], [13], [14].
Specimens, blind of their clinico-pathological, and immunohistochemical data. The cases were collected from the Pathology Department at the Kasr El-Aini hospital in the time period between May 2018 and February 2019.

The data collected from the pathology reports of the cases included age and sex of patient, tumor size, type, and the degree of dysplasia as regard cases of adenoma. Regarding carcinoma cases, data collected included age and sex of patient, size of tumor, as well as the lymph node status.

The paraffin blocks of the tumor tissue were serially sectioned at 4 μm thickness, stained with routine hematoxylin and eosin stains for pathological examination. The tumors were histologically typed according to the latest available World Health Organization recommendations [15].

Tumors histological grading was performed according to the World Health Organization recommendations [2]. Tumors staging was performed using the TNM staging system and the cases were further divided into prognostic stages [16]. Modified Duke’s staging was also performed [17].

The tumor sections were also examined for the presence of lymphovascular invasion and perineural invasion.

For immunostaining, additional serial sections were prepared from the paraffin blocks and mounted on charged slides. Heat mediated antigen retrieval was performed with citrate buffer pH 6 in automated water bath (Dako PT link, PT101). Sections were stained for anti-connexin 43 antibody (Rabbit Polyclonal Anti-Connexin 43/GJA1 antibody [EPR21153] ab217676) obtained from Abcam and used at a dilution of 1:250. Immunohistochemical staining was performed in an autostainer (Dako Autostainer Link 48) using a polymer-based detection system (Dako EnVision™ FLEX, K8000). Diaminobenzidine was used as chromogen and hematoxylin as counterstain. Sections of normal human prostate tissue were used as positive control according to the manufacturer’s recommendation.

The immunohistochemical staining was analyzed. The percentage of positively stained cells in normal, adenomatous, and cancerous tissues was assessed according to a 3-point scale: 0 (<10% positively stained cells), 1+ (10–50% positively stained cells), and 2+ (>50% positively stained cells). The results of Cx 43 immunostaining were expressed as Cx 43-positive (level of expression 1+ and 2+) and Cx 43-negative (level of expression 0) [18].

A substrate of cases was also stained immunohistochemically against β-catenin and Cyclin D1 using the same above methods.

Microsoft Excel 2010 was used for data entry and the Statistical Package for the Social Sciences (SPSS version 21) was used for data analysis. Simple descriptive statistics (arithmetic mean and standard deviation) used for summary of quantitative data and frequencies used for qualitative data.

Finally, microscopic photos were captured using a digital camera attached to an Olympus microscope model BX 51.

Results

This study is a retrospective study including 70 randomly selected cases; 20 cases of colorectal adenoma and 50 cases of carcinoma obtained from endoscopic and colectomy specimens. The cases were collected from the Kasr Al-Aini Hospital in the time period between May 2018 and February 2019. The clinico-pathological data, histological examination, and immunohistochemical results are summarized in Table 1.

In the present study, connexin 43 (Cx 43) was evaluated in colorectal adenoma and carcinoma cases. Sections from normal prostate gland were stained in the same runs with our colorectal adenoma and carcinoma cases, as positive control as instructed by the primary antibody’s manufacturer. It was strongly and consistently expressed in the basal cells of normal human prostate glands. However, it was not expressed in all of colorectal adenoma and carcinoma cases.

Discussion

In the present study, connexin 43 (Cx 43) was evaluated in colorectal adenoma and carcinoma cases. Sections from normal prostate gland were stained in the same runs with our colorectal adenoma and carcinoma cases, as positive control as instructed by the primary antibody’s manufacturer. It was strongly and consistently expressed in the basal cells of normal human prostate glands (Figure 1c). However, it was not expressed in all of colorectal adenoma and carcinoma cases (Figure 1d and e). Hence, we suggest that Cx 43 may act as tumor suppressor gene and its expression is lost early in colorectal carcinogenesis.

It was only expressed focally in normal mucosa adjacent to adenocarcinoma (Figure 1a and b) that was in concordance with Nemeth et al. [19], Dubina et al. [20] and Kanczuga-Koda et al. [21] where Cx 43 was sparsely distributed in the human colonic epithelial cells. The notion that connexins are able to form gap junctions in normal colonic mucosa is further supported by Western blot analysis of protein extracts from normal colon tissue [22].
In concordance to our results, Sirnes et al. have shown that Cx 43 is either absent or aberrantly localized in colon cancer cell lines and colorectal carcinomas, which is associated with loss of GJIC. They studied a cohort of 674 colorectal carcinoma patients. About 63% of patients had weak or no expression of Cx 43 in tumors [22]. Although some colon cancer cell lines express Cx 43 at the protein level in vitro, they usually do not form gap junctions, probably because of aberrant regulation of the intracellular trafficking of Cx 43. The mechanisms underlying such impaired Cx 43 trafficking remain to be elucidated, but may involve dysregulation of the signaling pathways involved in regulating the assembly of Cx 43 into gap junctions or Cx 43 endocytosis and postendocytic sorting [13]. Furthermore, loss of Cx 43 expression was significantly correlated with shorter relapse-free survival and overall survival. Loss of Cx 43 further identified among Sage I and Stage II patients with reduced relapse-free and overall survival. However, this study was carried on cell lines and they combine both immunohistochemistry and Western blot techniques. They concluded that Cx 43 acts as a CRC tumor suppressor and that loss of Cx 43 expression during CRC development is associated with reduced patient survival [22].

Furthermore, Ismail et al. demonstrated that Western blotting using anti-Cx 43 antibody indicated that the expression of Cx 43 was significantly downregulated in 75% of colon cancer samples and immunohistochemical analysis of the tissue samples confirmed the downregulation of the Cx 43. Cx 43 downregulation showed significant association (p < 0.05) with the histological type and tumor invasion properties of the cancer. They suggested that loss of Cx 43 may be an important event in colon carcinogenesis and tumor progression, providing significant insights about

### Table 1: Clinico-pathologic features and Cx 43 expression

| Parameter                  | Adenoma cases | Carcinoma cases |
|----------------------------|---------------|-----------------|
| n (%)                      | Cx 43 (positive expression) | Cx 43 (negative expression) |
| Age (27–76 years, mean 59.8±11.83) | 20 (28.6) | 50 (71.4) |
| Sex                        | Male | 14 (70) | 22 (44) |
|                           | Female | 6 (30) | 28 (56) |
| Site                       | Left colon | 11 (55) | 19 (38) |
|                           | Right colon | 4 (20) | 19 (38) |
|                           | Rectum | 5 (25) | 12 (24) |
| Size                       | <2 cm | 17 (85) | 38 (64) |
|                           | >2 cm | 3 (15) | 2 (3) |
| Histologic grade           | Low grade dysplasia | 14 (70) | 30 (48) |
|                           | High grade dysplasia | 6 (30) | 10 (16) |
| Type                       | Tubular | 11 (55) | 22 (39) |
|                           | Tubulovillous | 4 (20) | 7 (12) |
|                           | Serrated | 5 (25) | 8 (14) |
| Carcinoma cases            | 50 (71.4) | 0 (0) |
| Age (30–75 years, mean 54±11.62) | 0 (0) | 0 (71.4) |
| Sex                        | Male | 22 (44) | 22 (44) |
|                           | Female | 28 (56) | 28 (56) |
| Site                       | Left colon | 19 (38) | 19 (38) |
|                           | Right colon | 19 (38) | 19 (38) |
|                           | Rectum | 12 (24) | 12 (24) |
| Size                       | <3 cm | 12 (24) | 24 (40) |
|                           | >3 cm | 26 (48) | 28 (48) |
| Histologic types           | Adenocarcinoma | 41 (62) | 41 (62) |
|                           | Mucoid carcinoma | 9 (18) | 9 (18) |
| Histologic grade of adenocarcinoma | Grade I | 0 (0) | 0 (0) |
|                           | Grade II | 30 (73) | 30 (73) |
|                           | Grade III | 11 (27) | 11 (27) |
| T stage                    | T1 | 0 (0) | 0 (0) |
|                           | T2 | 4 (8) | 4 (8) |
|                           | T3 | 36 (72) | 36 (72) |
|                           | T4 | 10 (20) | 10 (20) |
| N stage                    | N1 | 18 (36) | 18 (36) |
|                           | N2 | 16 (32) | 16 (32) |
|                           | N3 | 16 (32) | 16 (32) |
| M stage                    | M0 | 49 (98) | 49 (98) |
|                           | M1 | 1 (2) | 1 (2) |
| Stage                      | Stage I | 3 (6) | 3 (6) |
|                           | Stage II | 15 (30) | 15 (30) |
|                           | Stage III | 31 (62) | 31 (62) |
|                           | Stage IV | 1 (2) | 1 (2) |
| Modified Duke’s class      | A | 0 (0) | 0 (0) |
|                           | B1 | 3 (6) | 3 (6) |
|                           | B2 | 15 (30) | 15 (30) |
|                           | C1 | 23 (46) | 23 (46) |
|                           | C2 | 8 (16) | 8 (16) |
|                           | D | 1 (2) | 1 (2) |
| Lymphovascular invasion    | Positive | 16 (32) | 16 (32) |
|                           | Negative | 34 (68) | 34 (68) |
| Perineural invasion        | Positive | 18 (36) | 18 (36) |
|                           | Negative | 32 (64) | 32 (64) |

Figure 1: (a and b) Cx 43 expression in normal colonic mucosa, (c) Cx 43 expression in basal cell layer of prostatic glands "positive control," (d) negative Cx 43 expression in colonic adenocarcinoma, (e) negative Cx 43 expression in mucoid carcinoma, (f) positive β-catenin membranous staining in adenocarcinoma
the tumor suppressive properties of the Cx 43 and its potential as a diagnostic marker for colon cancer [14].

Dubina et al. also considered that Cx 43 acts as tumor suppressor since their function or expression is frequently aberrant in tumor cells. They have demonstrated that connexin 43 is specifically and quite frequently mutated in human colon sporadic adenocarcinomas. All tumor-associated mutations led to a shift of reading frame causing premature stop codons and truncation of the multifunctional carboxyl-terminal domain of the protein. Expression of mutated connexin 43 proteins was restricted to invasive structures of tumors. These findings suggest that mutational alterations of connexin 43 are involved in advanced stages of progression of human colon cancer toward malignancy [20].

Since the interaction between connexins of adjacent cells is not strong enough to maintain the cytoplasmic membranes of the neighboring cells together and to form the channel, the formation and maintenance of gap junctions require the presence of cell adhesion molecules [23], [24]. So substrate of cases was immunohistochemically stained with the adhesion molecule β-catenin. The majority of cases were negative apart from a focal positive area where focal membranous staining was noted between the tumor cells (Figure 1f). The correlation between Cx 43 and β-catenin; being both were downregulated in our work strengthen our conclusion that Cx 43 has tumor suppressor properties being lost in our cases. This finding was similar to Kanczuga-Koda et al. who found a statistically significant positive correlation between β-catenin and Cx 43 in colorectal carcinoma cases [21].

Cx 43 was also shown to participate in cell cycle regulation [25], [26]. Cyclin D1 is a protein required for progression through the G1 phase of the cell cycle. During the G1 phase, it is synthesized rapidly and accumulates in the nucleus and is degraded as the cell enters the S phase [27]. A substrate of cases was stained with Cyclin D1 and they found to be negative, this finding was approximate to Qi et al. who found significant correlation between the protein expression rates of Cyclin D1 and Cx 43 (p < 0.05) in rectal cancer specimens [28].

Decreased gap junctional communication and reduced connexin expression were subsequently observed in several cancer types. Moreover, many growth factors, oncogenes and tumor promoters are potent inhibitors of GJIC [13].

Strengthening our results, several lines of experimental evidence indicate that connexins may act as tumor suppressors. First, restoration of GJIC by transfection of connexin genes into tumorigenic cells has been shown to normalize growth in vitro and in vivo [29], [30], [31], [32]. Second, downregulation of connexins by small interfering RNA has been found to result in more aggressive growth of cancer cells [32]. Third, knock-out of connexin genes in mice results in increased susceptibility to chemical or radiation-induced tumor formation [33], [34], [35]. Collectively, these observations are in concordance with our results in which the connexins may act as tumor suppressors, and they are considered as potential targets for cancer chemoprevention and chemotherapy [10], [11], [12].

Although several studies have shown that connexins are downregulated in colorectal carcinomas, some studies; in contrast to, our results have observed enhanced connexin expression. Han et al. stated that Cx 43 cytoplasmic expression increased progressively in the colon adenocarcinoma sequence in both the epithelial and stromal components. In the epithelial component, Cx 43 was expressed lower in Stage I adenocarcinomas compared to Stage III/IV. In addition, Cx 43 was relatively increased in the adenocarcinoma at the invasive tumor front in all stages. Cytoplasmic expression of Cx 43 was frequently observed in colon cancer cells. In addition, we found that the level of Cx 43 expression was significantly associated with higher AJCC Stage III/IV but did not have impact on the histological grading [36].

Another study showed higher Cx 43 expression in adenomas compared to healthy colonic mucosa suggesting an active role of Cx 43 in the process of carcinogenesis. Moreover, higher Cx 43 expression was found in the colonic mucosa surrounding advanced colorectal adenoma [37]. Stromal Cx 43 expression in CRC was found to be higher in more advanced CRC showing that it is a possible indicator of metastatic potential of colorectal adenocarcinoma [18].

Regarding the role of Cx 43 in other different tumors, many studies also reported its tumor suppressor effects. Ableser et al. suggest that Cx 43 can act as a tumor suppressor during melanoma tumorigenesis [38]. Solan et al. who studied the role of Cx 43 in pancreatic adenocarcinoama cell lines show decreased or altered connexin expression and/or localization [39]. Silencing connexin 43 induces cell cycle entry and invasion in non-neoplastic mammary epithelial cells [40]. Connexin 43 also suppresses lung cancer stem cells [41]. Yet different organs but they stated that it has tumor suppressor properties.

Regarding role of other connexins in CRC, patients with high levels of Cx 26 in the primary tumor have been reported to have a higher probability of developing lung metastasis. Furthermore, lung metastases, but not lymph node or liver metastases, have a higher level of Cx 26 expression than the corresponding primary colorectal tumor. Cx 26 localizes both in intracellular compartments and at the plasma membrane in the metastatic cells, indicating a possible role for GJIC during metastasis. Thus, Cx 26 is a promising therapeutic target, particularly for CRC patients who develop lung metastasis [42].

The finding that several connexin isoforms are expressed in colonic tissue, along with the fact that they
function in a redundant manner, makes it challenging to understand the roles of the specific connexin isoform in the normal colonic mucosa and in CRC pathogenesis. It will also be important to define which isoforms are expressed at the protein level in the normal colonic epithelium and to obtain a better understanding of how their expression changes during CRC progression [13].

The fact that connexins may be involved in both tumor suppression and tumor progression should be carefully evaluated before connexins can be considered as targets in cancer therapy. On the one hand, restoration of connexin expression and functional gap junctions may result in reduced tumor growth; on the other hand, increasing connexin expression may in other circumstances leads to increased cancer cell invasion. A central step toward determining whether connexins could represent beneficial targets in CRC prevention and therapy will be to obtain a better understanding of the molecular basis underlying their dysregulation during disease development.

Conclusion

Cx 43 is a tumor suppressor that is lost early in colorectal carcinogenesis and can be considered as potential target for cancer chemoprevention and chemotherapy aiming at restoration of normal connexin expression and functional gap junctions.

References

1. Enkhbat T, Nishi M, Takasu C, Yoshikawa K, Jun H, Tokunaga T, et al. Programmed cell death ligand 1 expression is an independent prognostic factor in colorectal cancer. Anticancer Res. 2018;38(6):3367-73. https://doi.org/10.21873/anticancer.12603 PMid:29648685
2. Hamilton SR, Bosman FT, Boffetta P. In: Bosman FT, Carneiro F, Hruban RH and Theise ND, editors. Carcinoma of the colon and rectum. In: Kleihues P, Louis DN, editors. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC Press; 2010. p. 132-46.
3. Khorsheed E. Gastrointestinal tract tumors. In: Mokhatr NM, MA Ghoneim, MH Hussein, editors. Cancer Pathology Registry 2000-2011. Bethesda, Maryland: National Cancer Institute; 2016. p. 32-48.
4. Loewenstein WR, Kanno Y. Intercellular communication and the control of tissue growth: Lack of communication between cancer cells. Nature. 1996;209(5029):1248-9. https://doi.org/10.21873/anticancer.12603 PMid:5956321
5. Aasen T, Mesnil M, Naus CC, Lampe PD, Laird DW. Gap junctions and cancer: Communicating for 50 years. Nat Rev Cancer. 2016;16(12):775-88. https://doi.org/10.1038/nrc.2016.105 PMid:27782134
6. Saez JC, Leybaert L. Hunting for connexin hemichannels. FEBS Lett. 2014;588(8):1205-11. https://doi.org/10.1016/j.febslet.2014.03.004 PMid:24631534
7. Laird DW, Lampe PD. Therapeutic strategies targeting connexins. Nat Rev Drug Discov. 2018;17(12):905-21. https://doi.org/10.1038/nrd.2018.138 PMid:30310236
8. Delvaeye T, Vandenabeele P, Bultynck G, Leybaert L, Krysko DV. Therapeutic targeting of connexin channels: New views and challenges. Trends Mol Med. 2018;24(12):1036-53. https://doi.org/10.1016/j.molmed.2018.10.005 PMid:30424929
9. Tan LW, Bianco T, Dobrovic A. Variable promoter region CpG island methylation of the putative tumor suppressor gene connexin 26 in breast cancer. Carcinogenesis. 2002;23(2):231-6. https://doi.org/10.1093/carcin/23.2.231 PMid:11872627
10. Kandouz M, Batist G. Gap junctions and connexins as therapeutic targets in cancer. Expert Opin Ther Targets. 2010;14(7):681-92. https://doi.org/10.1517/14728222.2010.487866 PMid:20446866
11. King TJ, Bertram JS. Connexins as targets for cancer chemoprevention and chemotherapy. Biochim Biophys Acta. 2005;1719(1-2):146-60. PMid:16263076
12. Naus CC, Laird DW. Implications and challenges of connexin connections to cancer. Nat Rev Cancer. 2010;10(6):435-41. https://doi.org/10.1038/nrc2841 PMid:20495577
13. Sirnes S, Lind GE, Bruun J, Fykderu TA, Mesnil M, Lothe RA, et al. Connexins in colorectal cancer pathogenesis. Int J Cancer. 2015;137(1):1-11. https://doi.org/10.1002/ijc.28911 PMid:24752574
14. Ismail R, Rashid R, Andradi K, Parray FQ, Besina S, Shah MA, et al. Pathological implications of Cx43 down-regulation in human colon cancer. Asian Pac J Cancer Prev. 2014;15(7):2987-91. https://doi.org/10.7314/apjcp.2014.15.7.2987 PMid:24815435
15. Bosman F, Carneiro F, Hruban R, Theise N. Tumors of the colon and rectum. In: Kleihues P, Louis DN, editors. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC Press; 2010. p. 132.
16. Jessup JM, Goldberg RM, Asare EA, Benson AB 3rd, Brierley JD, Chang GJ, et al. Definitions of AJCC TNM. In: Amin MB, Edge SB, Greene FL., editors. AJCC Cancer Staging Manual. 8th ed. Berlin: Springer; 2017. p. 268-9.
17. Bresalier RS. Colorectal Cancer. In: Feldman M, Friedman LS, Brandt LJ., editors. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 9th ed. Philadelphia, PA: Elsevier; 2010. p. 2191-238. https://doi.org/10.1016/b978-1-4160-1809-2.00123-2
18. Radić J, Krušlin B, Šamija M, Ulamec M, Milošević M, Jazvić M, et al. Connexin 43 expression in primary colorectal carcinomas in patients with Stage III and IV disease. Anticancer Res. 2016;36(5):2189-96. PMid:27127122
19. Nemeth L, Maddur S, Puri P. Immunolocalization of the gap junction protein connexin 43 in the interstitial cells of cajal in the normal and Hirschsprung’s disease bowel. J Pediatr Surg. 2000;35(6):823-8. https://doi.org/10.1053/psu.2000.6851 PMid:10873019
20. Dubina MV, Iatchki NA, Popov DE, Vasi'lev SV, Krutovskikh VA. Connexin 43, but not connexin 32, is mutated at advanced stages of human sporadic colon cancer. Oncogene.
Ayad et al. Expression of Connexin 43 in Colorectal Carcinoma

2.21(32):4992-6. https://doi.org/10.1038/sj.onc.1205630
PMid:12118378

21. Kanczuga-Koda L, Sulkowski S, Koda M, Sobaniec-Lotowska M, Sulkowski M. Expression of connexins 26, 32 and 43 in the human colon—an immunohistochemical study. Folia Histochem Cytobiol. 2004;42(4):203-7. https://doi.org/10.5603/fhc.2013.0043
PMid:15704465

22. Simes S, Bruun J, Kolberg M, Kjenseth A, Lind GE, Svinland A, et al. Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. Int J Cancer. 2012;131(3):570-81. https://doi.org/10.1002/ijc.26392
PMid:21866551

23. Hsu M, Andl T, Li G, Meinkoth JL, Herlyn M. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci. 2000;113(Pt 9):1535-42.
PMid:10751145

24. Fujimoto K, Nagafuchi A, Tsukita S, Kuraoka A, Ohokuma A, Shibata Y. Dynamics of connexins, E-cadherin and alpha-catenin on cell membranes during gap junction formation. J Cell Sci. 1997;110(Pt 3):311-22.
PMid:9057084

25. Solan JL, Lampe PD. Connexin phosphorylation as a regulatory event linked to gap junction channel assembly. Biochim Biophys Acta. 2005;171(2):154-63. https://doi.org/10.1016/j.bbamem.2004.09.013
PMid:15955300

26. Decrock E, De Vuyst E, Vinken M, Van Moorhem M, Vranckx K, Wang N, et al. Connexin43 hemichannels contribute to the propagation of apoptotic cell death in a rat C6 glioma cell model. Cell Death Differ. 2009;16(1):151-63. https://doi.org/10.1038/cdd.2008.138
PMid:18820645

27. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7(5):811-21. https://doi.org/10.1101/gad.7.5.812
PMid:8491378

28. Qi F, Yuan Y, Zhi X, Huang Q, Chen Y, Zhuang W, et al. Synergistic effects of AKAP95, cyclin D1, cyclin E1, and Cx43 in the development of rectal cancer. Int J Clin Exp Pathol. 2015;8(2):1666-73.
PMid:25973052

29. King TJ, Fukushima LH, Yasui Y, Lampe PD, Bertram JS. Inducible expression of the gap junction protein connexin43 decreases the neoplastic potential of HT-1080 human fibrosarcoma cells in vitro and in vivo. Mol Carcinog. 2002;35(1):29-41. https://doi.org/10.1002/mc.10071
PMid:12203365

30. McLachlan E, Shao Q, Wang HL, Langlois S, Laird DW. Connexins act as tumor suppressors in three-dimensional mammary cell organoids by regulating differentiation and angiogenesis. Cancer Res. 2006;66(20):9886-94. https://doi.org/10.1158/0008-5472.can-05-4302
PMid:17047050

31. Zhang D, Chen C, Li Y, Fu X, Xie Y, Li Y, et al. Cx31.1 acts as a tumour suppressor in non-small cell lung cancer (NSCLC) cell lines through inhibition of cell proliferation and metastasis. J Cell Mol Med. 2012;16(5):1047-59. https://doi.org/10.1111/j.1582-4934.2011.01389.x
PMid:21777377

32. Shao Q, Wang H, McLachlan E, Veitch GI, Laird DW. Down-regulation of Cx43 by retroviral delivery of small interfering RNA promotes an aggressive breast cancer cell phenotype. Cancer Res. 2005;65(7):2705-11. https://doi.org/10.1158/0008-5472.can-04-2367
PMid:15805269

33. Avanzo JL, Mesnil M, Hernandez-Biazquez FJ, Mackowiak II, Mori CM, da Silva TC, et al. Increased susceptibility to urethane-induced lung tumors in mice with decreased expression of connexin43. Carcinogenesis. 2004;25(10):1973-82. https://doi.org/10.1093/carcin/bgh193
PMid:15166089

34. Dagli ML, Yamasaki H, Kutzovskikh V, Omori Y. Delayed liver regeneration and increased susceptibility to chemical hepatocarcinogenesis in transgenic mice expressing a dominant-negative mutant of connexin32 only in the liver. Carcinogenesis. 2004;25:483-92. https://doi.org/10.1093/carcin/bgh050

35. King TJ, Lampe PD. Mice deficient for the gap junction protein connexin32 exhibit increased radiation-induced tumorigenesis associated with elevated mitogen-activated protein kinase (p44/Erk1, p42/Erk2) activation. Carcinogenesis. 2004;25(5):669-80. https://doi.org/10.1093/carcin/bgh071
PMid:14742325

36. Han Y, Zhang PJ, Chen T, Yum SW, Pasha T, Furth EE. Connexin43 expression increases in the epithelium and stroma along the colonic neoplastic progression pathway: Implications for its oncogenic role. Gastroenterol Res Pract 2011;2011:561719. https://doi.org/10.1155/2011/561719
PMid:21754925

37. Bišćanin A, Ljubičić N, Boban M, Baličević D, Pavić I, Bišćanin MM, et al. CX43 Expression in colonic adenomas and surrounding mucosa is a marker of malignant potential. Anticancer Res. 2016;36(10):5437-42. https://doi.org/10.21873/anticancerres.11122
PMid:27798912

38. Ableser MJ, Penuela S, Lee J, Shao Q, Laird DW. Connexin 43 reduces melanoma growth within a keratinocyte microenvironment and during tumorigenesis in vivo. J Biol Chem. 2014;289(3):1592-603. https://doi.org/10.1074/jbc.M113-1538-7445.am2014-2467
PMid:24297173

39. Solan JL, Hingorani SR, Lampe PD. Changes in connexin43 expression and localization during pancreatic cancer progression. J Membrane Biol. 2012;245(5-6):255-62. https://doi.org/10.1007/s00232-012-9446-2
PMid:22729649

40. Fostok SF, Bazzoun D, Lelievre SA, El-Sibai M, Talhouk RS. Silencing connexin 43 induces cell cycle entry and invasion in non-neoplastic mammary epithelial cells. Cancer Res. 2018;78(13 Suppl):4505. https://doi.org/10.1158/1538-7445.am2018-4505

41. Ruch RJ. Connexin43 suppresses lung cancer stem cells. Cancers. 2019;11(2):175. https://doi.org/10.3390/cancers11020175
PMid:30717421

42. Ezumi K, Yamamoto H, Murata K, Higashiyama M, Damdinsuren B, Nakamura Y, et al. aberrant expression of connexin 26 is associated with lung metastasis of colorectal cancer. Clin Cancer Res. 2008;14(3):677-84. https://doi.org/10.1158/1078-0432.ccr-07-1184
PMid:18245526